WOEBOT HEALTH

Alison Darcy was a clinical research psychologist at Stanford studying how technology could extend the reach of evidence-based psychological treatments. The access problem was stark: roughly 30 therapists per 100,000 people in the US, most with months-long waitlists, and most covered by insurance that did not include mental health.

CBT — cognitive behavioral therapy, the most evidence-backed form of talk therapy — does not require a human to deliver every component of it. Darcy founded Woebot in 2017 as a conversational AI that delivers CBT techniques through natural language chat.

The founding move was publishing a randomized controlled trial in JMIR Mental Health showing Woebot users had significantly lower depression and anxiety scores after two weeks compared to control. That paper turned a chatbot into a clinical product.

B2B licensing model. Woebot pivoted from consumer to enterprise and now licenses its platform to healthcare payers (insurance companies), health systems, pharmaceutical companies, and employee benefit providers.

The product sits inside clinical workflows as a digitally-delivered behavioral health tool. Pharma partnerships focus on conditions where Woebot can serve as a digital therapeutic companion alongside medication — including perinatal mental health and substance use disorders.

Revenue comes from enterprise contracts rather than subscriptions, providing more predictable recurring revenue than a consumer app.

Woebot — the core conversational AI delivering CBT, DBT, interpersonal therapy, and mindfulness techniques via natural language chat. Available 24/7 with no appointment or waitlist.

Woebot for Teens — adapted for adolescent mental health, with FDA Breakthrough Device Designation for adolescent depression. Perinatal mental health program — designed for pregnant women and new mothers experiencing anxiety and depression, developed with healthcare provider partners.

Substance use support — digital therapeutic support program for people managing addiction and recovery. All products are deployed through enterprise licensing, not consumer downloads.

Clinical evidence is the growth engine and the moat. Woebot has published more peer-reviewed research on its platform than any comparable AI mental health company — and that evidence base opens enterprise doors that anecdote-backed competitors cannot enter.

FDA Breakthrough Device Designation for adolescent depression (2020) added regulatory credibility for US health system conversations. The.5M strategic investment from Leaps by Bayer in 2022 opened pharmaceutical partnerships for condition-specific deployments.

Alison Darcy's inclusion in the 2023 TIME100 AI list generated profile and credibility in the AI health debate. NHS partnerships in the UK provide a non-US institutional footprint most US competitors lack.

The AI mental health market has become saturated with tools of wildly varying quality. Woebot's evidence-based positioning is correct but increasingly claimed by every competitor.

Institutional buyers — payers, health systems, employers — struggle to distinguish research-backed tools from wellness apps with a rebrand. Converting clinical proof into procurement decisions is slower and harder than it should be.

There is also a genuine ceiling: Woebot is most effective for mild-to-moderate symptoms. For severe mental illness, it is a supplement at best.

Holding to that honest positioning against commercial pressure to claim broader utility is an ongoing tension.

Series A of M (March 2018) led by New Enterprise Associates (NEA) with participation from Andrew Ng's AI Fund. Series B of 0M (July 2021) co-led by Jazz Venture Partners and Temasek.

Strategic investment of.5M from Leaps by Bayer (2022). Total raised approximately 24M.